Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cellectis S.A. ADR (NQ: CLLS )

1.970 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.970
Bid (Size) 1.980 (8)
Ask (Size) 2.020 (40)
Prev. Close 1.970
Today's Range 1.970 - 1.970
52wk Range 1.680 - 4.100
Shares Outstanding 45,484,310
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies
From Cellectis Inc.
Via GlobeNewswire
Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023
From Cellectis Inc.
Via GlobeNewswire

Performance

YTD
-13.22%
-13.22%
1 Month
+7.95%
+7.95%
3 Month
-7.73%
-7.73%
6 Month
-9.63%
-9.63%
1 Year
-39.38%
-39.38%

More News

Read More
Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors
From Cellectis Inc.
Via GlobeNewswire
Recap: Cellectis Q1 Earnings
Via Benzinga
Expert Ratings for Cellectis
Via Benzinga
Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023
From Cellectis Inc.
Via GlobeNewswire
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023
From Cellectis Inc.
Via GlobeNewswire
Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
A Preview Of Cellectis's Earnings
Via Benzinga
Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023
From Cellectis Inc.
Via GlobeNewswire
Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab
From Cellectis Inc.
Via GlobeNewswire
Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22
From Cellectis Inc.
Via GlobeNewswire
Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of €20 million
From Cellectis Inc.
Via GlobeNewswire
Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Cellectis Inc.
Via GlobeNewswire
Earnings Scheduled For March 8, 2023
Via Benzinga
Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023
From Cellectis Inc.
Via GlobeNewswire
There's a Lot of Upside For Emerging Gene-Editing Companies
Via MarketBeat
Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares
From Cellectis Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information
From Cellectis Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Cellectis Announces Pricing of Follow-On Offering
From Cellectis Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.